Escalating Public Spending: Semaglutide Off-Lab...

By João L. Carapinha

April 17, 2026

Semaglutide off-label use for weight loss is at the centre of a suspected €250 million fraud uncovered by Portugal’s Judicial Police within the National Health Service (SNS). According to the investigation reported on 15 April 2026, roughly half o...
Advancing B7-H3 Targeted Therapy for Relapsed Extensive-Stage Small Cell Lung...
Advancing Inclusive Healthcare Strategies Through Social Impact and Sustainab...
Advancing Access: Generic Dapagliflozin Approval Enhanced for Type 2 Diabetes...
Closing the East-West Divide: Addressing Healthcare Investment Disparities in...
Utah’s AI Medication Prescribing Risks: Navigating the Challenges of Au...
Safeguarding Access: Navigating Pharmaceutical Cost Pressures in Portugal
Inequality-Adjusted ICER: Enhancing Cost-Effectiveness in Health Technology E...
Semaglutide Distribution Flexibility: EMA Approves Room Temperature Delivery ...
Shift in Portuguese Pediatric Vaccination Policy: Evolving Perspectives on Ri...
Advancements in Pulsed Field Ablation: The VARIPULSE Pro Platform Launch
Expansion of Community Health Programs by Novartis to Tackle Global Health Di...
Antimicrobial Resistance Art: Bridging Science and Health Through Visual Stor...